CMC stands for Chemistry, Manufacturing, and Controls, and it refers to the entire body of work that ensures a drug can be made consistently, safely, and at the right quality every time. If drug discovery is about finding the right molecule, CMC development is about turning that molecule into a real, reliable product that regulators will allow patients to take. It covers everything from how the active ingredient is synthesized to how the final tablet or injection is packaged, tested, and kept stable on a shelf.
The Four Pillars of CMC
The FDA organizes CMC requirements around four core areas. First is the composition and control of both the drug substance (the active ingredient itself) and the drug product (the finished form a patient actually receives, such as a tablet, capsule, or solution). Second is the manufacturer and manufacturing process. Third is the identity, quality, purity, and strength of the product. Fourth is stability, meaning proof that the drug remains effective over time under real-world storage conditions.
These four pillars apply from the earliest clinical trials through commercial manufacturing. What changes across the development timeline is how much detail and data regulators expect for each one.
How CMC Work Evolves Across Clinical Phases
During Phase 1 trials, when a drug is first tested in humans, CMC requirements are relatively light. Regulators need a brief description of how the active ingredient is made, preliminary stability data, and a basic overview of how the finished product is manufactured and packaged. The goal at this stage is to confirm the drug is safe enough to give to a small number of volunteers, not to lock down a commercial process.
By Phase 2, companies must provide safety updates on the earlier data, test results for clinical trial materials produced since the original filing, and a step-by-step description of how the finished dosage form is made. The process is getting more defined, but there is still room for changes.
Phase 3 is where CMC work intensifies dramatically. The drug substance now requires a detailed description of the synthetic or manufacturing process, along with fully validated analytical procedures ready for regulatory submission. The drug product needs complete characterization, documented manufacturing controls, acceptance criteria for every test, and detailed stability data including stress studies that push the product to its limits. This is the stage where companies must prove they can manufacture the drug at commercial scale with consistent quality.
Analytical Testing and Method Validation
A large part of CMC development involves creating and validating the tests that prove a drug is what it claims to be. These analytical methods must demonstrate several things. Specificity means the test can identify the active ingredient even when impurities, degradation products, or inactive ingredients are present. Accuracy confirms the test gives results close to the true value, typically demonstrated across multiple concentrations with replicate measurements. Precision shows the test gives the same answer when repeated under the same conditions.
Tests also need defined detection and quantitation limits. The detection limit is the smallest amount of a substance the method can reliably sense, while the quantitation limit is the smallest amount it can measure with acceptable accuracy. These thresholds matter because they determine whether the method can catch trace impurities that could affect patient safety. International guidelines set specific statistical formulas for calculating both limits, and companies must report these values along with the approach used to determine them.
Stability Testing and Shelf Life
Every drug degrades over time. Stability testing establishes how quickly that happens and under what conditions, which directly determines the expiration date printed on the label. International guidelines require three tiers of testing. Long-term studies store the product at 25°C and 60% relative humidity (or 30°C and 65% humidity) for at least 12 months. Accelerated studies crank conditions up to 40°C and 75% humidity for 6 months to simulate what might happen over a longer period. An intermediate study at 30°C and 65% humidity bridges the gap when needed.
Products packaged in containers that let moisture pass through, like certain plastic vials, face different humidity requirements because the packaging itself affects degradation. For these products, long-term testing uses lower humidity levels (40% or 35% relative humidity depending on temperature), and accelerated studies are run at very low humidity to stress-test moisture loss. The data from all of these studies must be included in regulatory submissions and updated throughout the product’s lifecycle.
Process Validation and Scale-Up
Making a drug in a lab is very different from making millions of doses in a factory. Process validation is the formal proof that a manufacturing process works reliably at commercial scale, and the FDA breaks it into three stages.
Stage 1, Process Design, is where the commercial manufacturing process is defined based on everything learned during development and scale-up. Stage 2, Process Qualification, evaluates whether that design can actually produce consistent results in a real manufacturing environment. Stage 3, Continued Process Verification, is ongoing monitoring during routine production to confirm the process stays in control over time. This third stage never really ends. It continues for as long as the product is on the market.
Quality by Design
Modern CMC development increasingly follows an approach called Quality by Design, or QbD. Instead of testing quality into a product after it’s made, QbD builds quality in from the start by linking the desired clinical performance to specific product attributes, then designing a formulation and process that reliably deliver those attributes.
QbD uses tools like risk assessments, statistical design of experiments, mechanistic models, and real-time process monitoring to understand which variables matter most. The practical benefit is that companies shift resources from fixing problems after they happen to preventing them in the first place. It also gives manufacturers more flexibility, because when you deeply understand how your process works, regulators are more willing to allow adjustments within a proven range without requiring new approvals for every minor tweak.
Biologics vs. Small Molecules
CMC development is significantly more complex for biologics (proteins, antibodies, cell therapies, gene therapies) than for traditional small-molecule drugs. Biologics are large, structurally intricate molecules produced by living cells, and manufacturing variability can directly impact whether the product is safe and effective. A small change in cell culture conditions, purification steps, or storage temperature can alter the final product in ways that matter clinically.
Because of this sensitivity, biologics require more extensive characterization using multiple independent analytical methods to fully define the product’s attributes. Process controls must be tighter, and stability considerations are more demanding. The FDA has signaled some flexibility for cell and gene therapies specifically, allowing manufacturers to make minor process changes between clinical phases without overly burdensome comparability data, and permitting flexibility in setting product release specifications when justified by the nature of the product. There is also no fixed requirement for a specific number of process validation batches for these therapies, which reflects the reality that some advanced therapies are made in very small quantities.
Post-Approval CMC Changes
CMC work does not stop once a drug is approved. Manufacturers regularly need to change suppliers, update equipment, modify processes, or adjust specifications. The FDA categorizes these changes by their potential impact on the product.
- Minor changes can be implemented immediately but must be documented in an annual report to the FDA.
- Moderate changes require the company to submit a supplement at least 30 days before distributing product made with the change (called a CBE-30 supplement), or in some cases at the time of distribution.
- Major changes require a prior approval supplement, meaning the company must submit the change and receive explicit FDA approval before any product made with the new process can reach patients.
This tiered system lets routine improvements move forward without unnecessary delays while ensuring that changes with real quality or safety implications get appropriate scrutiny. Getting the classification right is a core CMC skill, because miscategorizing a change can lead to regulatory action or costly delays.